About Molecure S.A.
Molecure is a clinical stage biotechnology company that uses its world leading medicinal chemistry and biology capabilities to discover and develop first-in-class small molecule drug candidates that directly modulate the function of RNA and underexplored protein targets to treat multiple incurable diseases.
Our extensive in-house expertise has allowed us to collaborate with top global academic research institutes to access untapped, novel biology targets.
We have generated a diverse pipeline of seven distinct programs with the support of leading academic life science institutions globally, including Yale University, Rutgers University, the Flemish Institute for Biotechnology (VIB) in Ghent, the University of Michigan and the International Institute of Molecular and Cell Biology in Warsaw (IIMCB), which has significant expertise in RNA science and technology.
Our most advanced in-house drug candidate is OATD-01, a first in class dual chitinase inhibitor for the treatment of interstitial lung diseases, such as sarcoidosis and idiopathic pulmonary fibrosis, that is Phase II ready. A Phase II trial in patients with sarcoidosis is expected to start in 2023.
Our second proprietary candidate is OATD-02, an oral, potent and selective first in class, dual arginase inhibitor (ARG1 and ARG2) for the treatment of cancer, which is expected to advance to Phase 1 clinical development in the second half of 2022.
Molecure’s headquarters and laboratories are located in Warsaw, with an additional laboratory facility in Łódź, Poland. The company is listed on the Warsaw Stock Exchange (ticker: MOC).
Our team brings together exceptional capabilities in medicinal chemistry and translational science combined with an experienced entrepreneurial management team that are passionate about exploring the unexplored.